





Free Cash Flow Forecast



2004 Result Forecast

Total Sales Volume	Net Sales	Operating Profit	Net Income	Net ASP (Domestic)
113~115 bn sticks	2,500~2,600 bn won	850~950 bn won	450~500 bn won	550 won/pack

Free cash flow forecast

Major cash inflow			
Net Income	450~500 bn won		
Loss on conversion of CBs	140 bn won		
Depreciation	100 bn won		
Disposal of foreign bonds	300 bn won		
Total	990 ~ 1,040 bn won		

Free cash flow forecast			
CAPEX	210.8 bn won		
Dividend('03)	220 bn won		
Free cash flow	560 ~ 610 bn won		

Maintain current policy

"To place priority on maximizing shareholder value in utilizing excess cash"

+++ Policy I Intend to maintain high dividend policy

: Intend to pay 1,600 won per share for FY2004

+++ Policy II Intend to continue buyback and cancellation of treasury shares

: Buy back additional 24% of shares by the end of 2008

(14% for cancellation, 10% for holding in the form of treasury shares)

: In FY2004, 3 million shares are already under buyback process

In total, intend to buyback 300bn won worth of treasury shares

Buyback and cancellation of treasury shares

(KRW billion, thousand shares)		2002	2003	2004
Dividend per share (won)		1,400	1,600	1,600
Share buyback	Volume	11,428	0	Volume:?
	Amount	169.3	0	Amount: 300
Cancellation	Volume	9,549	3,000	- Shares bought back will be cancelled
	Amount	168.3	67.1	except 3million shares

CAPEX Plan



• Investment Policy

Tobacco Business: Continue to invest to enhance growth and competitiveness

Biz Diversification: Maintain policy of investing within 10% of net income

Conservative decision making based on profitability and synergies

CAPEX plan for FY 2004

(KRW billion)		FY03	FY04(E) (before)	FY04(E) (revised)	BAL	
Tobacco	Domestic	Youngjoo new plant	39.6	0	0	-
		Equipment	46.4	88.6	88.6	-
		Buildings	25.4	22.9	22.9	-
		Others	49.8	79.5	66.5	-13.0
	Sub-total		161.2	191.0	178.0	-13.0
	Overseas		-	4.0	4.0	-
Total		161.2	195.0	182.0	-13.0	
Business Diversification		4.4	15.8	28.8	+13.0	
Grand Total		165.6	210.8	210.8	-	

- KT&G's participation in right offering of Yungjin Pharm. has already been reflected on initial CAPEX plan in provisional budget.
- Now, this item was reclassified into revised CAPEX plan as the investment decision has been made recently.

